Zobrazeno 1 - 10
of 20
pro vyhledávání: '"N. Yu. Samaneva"'
Autor:
O. N. Selyutina, I. B. Lysenko, N. K. Guskova, I. A. Novikova, E. Yu. Zlatnik, T. F. Pushkareva, N. V. Nikolaeva, I. A. Kamaeva, N. Yu. Samaneva, E. A. Kapuza
Publikováno v:
Сибирский онкологический журнал, Vol 22, Iss 2, Pp 34-42 (2023)
Purpose: to study the level of LAG-3 expression on B-lymphocytes and the feasibility of using it as a marker for predicting response to therapy in patients with chronic lymphocytic leukemia (CLL).Material and Methods. The study included 40 patients w
Externí odkaz:
https://doaj.org/article/f0921a7e18b242d0b8a1712c5e189973
Autor:
N. K. Guskova, O. N. Selyutina, I. B. Lysenko, E. A. Guskova, A. K. Donskaya, N. Yu. Samaneva, E. A. Kapuza, T. F. Pushkareva
Publikováno v:
Онкогематология, Vol 17, Iss 4, Pp 81-87 (2022)
A complex clinical case of acute myelomonocytic leukemia with extramedullary lesion of the testis is presented. patient yu., born in 1968, applied to the National Medical Research Centre for Oncology (Rostov-on-don) after an injury to the inguinal re
Externí odkaz:
https://doaj.org/article/f549254ffea94c0c994ada2cb3f5fb31
Autor:
E. M. Frantsiyants, N. Yu. Samaneva, L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, S. N. Kabanov, A. V. Tishina
Publikováno v:
Южно-Российский онкологический журнал, Vol 2, Iss 3, Pp 6-12 (2021)
Purpose of the study. An analysis of blood levels of TGF-β, TGFR2, TNF-α, TNF-αR1, TNF-αR2, CD44 and MMP9 in patients with various biological subtypes of breast cancer receiving neoadjuvant chemotherapy.Materials and methods. This article present
Externí odkaz:
https://doaj.org/article/2fe7227ba9174294bd9da635b4d2499d
Autor:
L. Yu. Vladimirova, A. Eh. Storozhakova, I. L. Popova, S. N. Kabanov, N. A. Abramova, M. A. Teplyakova, N. M. Tikhanovskaya, K. A. Novoselova, A. A. Lyanova, L. A. Ryadinskaya, V. S. Myagkova, F. V. Alieva, E. A. Kalabanova, Ya. V. Svetitskaya, N. Yu. Samaneva, A. V. Tishina
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 64-74 (2021)
The development of a new direction in anticancer medical therapy – the use of immune checkpoint inhibitors targeting PD-1/ PD-L1 and CTLA-4 – has significantly changed the approach to tumor treatment in the last few years. The PD1 blocker nivolum
Externí odkaz:
https://doaj.org/article/d6b80369b6694d488584cf1468b3b89e
Autor:
O. I. Kit, L. Yu. Vladimirova, E. A. Kalabanova, A. E. Storozhakova, S. N. Kabanov, T. A. Snezhko, I. S. Mitashok, Ya. V. Svetitskaya, N. Yu. Samaneva, I. S. Kornilova, Yu. V. Przhedetskiy, V. V. Pozdnyakova, N. A. Abramova, I. L. Popova, N. M. Tikhanovskaya, A. A. Lyanova, K. A. Novoselova, L. A. Ryadinskaya
Publikováno v:
Сибирский онкологический журнал, Vol 20, Iss 2, Pp 85-92 (2021)
Background. Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The prognosis of the disease is largely determined by thebiological subtype of the tumor. Her2-posi
Externí odkaz:
https://doaj.org/article/37520b7ab3864c81a9d042b834977f6f
Autor:
L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, P. N. Meshcheryakov, S. V. Oskin, S. N. Kabanov, N. Yu. Samaneva, Ya. V. Svetitskaya, A. V. Tishina
Publikováno v:
Южно-Российский онкологический журнал, Vol 2, Iss 1, Pp 35-42 (2021)
Lung cancer is among the most common malignant diseases in Russia. In 80–90%, its morphological type is nonsmall cell lung cancer. Stage IV primary advanced lung cancer is diagnosed in 41% of patients. Median overall survival in stage IV patients r
Externí odkaz:
https://doaj.org/article/076418e5fa3841ad91f9a0ffc47fbf9e
Autor:
L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, E. V. Verenikina, S. N. Kabanov, Ya. V. Svetitskaya, N. Yu. Samaneva, N. M. Tikhanovskaya, K. A. Novoselova, O. G. Selezneva, A. V. Tishina
Publikováno v:
Южно-Российский онкологический журнал, Vol 1, Iss 3, Pp 67-74 (2020)
Ovarian cancer is one of the most common cancers in women. Growth and extension of the tumor are associated with active neoangiogenesis regulated by vascular endothelial growth factor (VEGF). Bevacizumab decreases VEGF activity and inhibits the tumor
Externí odkaz:
https://doaj.org/article/763932498d0d422f939dd5d540dfdd16
Autor:
L. Yu. Vladimirova, A. E. Storozhakova, T. A. Snezhko, L. K. Strakhova, N. A. Abramova, S. N. Kabanov, E. A. Kalabanova, N. Yu. Samaneva, Ya. V. Svetitskaya, A. V. Tishina
Publikováno v:
Южно-Российский онкологический журнал, Vol 1, Iss 2, Pp 46-51 (2020)
Breast cancer (BC) is the most common female cancer and the first leading cause of cancer death in women. Luminal phenotypes represent about 70% of this disease. Treatment for metastatic hormone‑dependent HER2‑negative breast cancer in most cases
Externí odkaz:
https://doaj.org/article/cb0804c095b04460bf60ce7513a4a3dd
Publikováno v:
Современная онкология, Vol 18, Iss 3, Pp 65-68 (2016)
The main treatment for metastatic soft tissue sarcomas is chemotherapy (CT); neutropenia is its frequent complication that is treated with various colony stimulating factors (CSFs). The purpose of the study was to assess the treatment effectiveness a
Externí odkaz:
https://doaj.org/article/7d11e1cbfd8c432083ec70940c092186
Autor:
L V Bolotina, L V Manziuk, V A Gorbunova, E I Kovalenko, G Z Mukhametshina, A I Khasanova, L Yu Vladimirova, I S Mitashok, E P Prokofyeva, I V Evstigneeva, I I Andreyashkina, N A Abramova, I L Popova, E V Karabina, A A Teterich, E A Gaysina, V A Chubenko, S V Limareva, N M Tikhanovskaya, A E Storozhakova, N Yu Samaneva, Ya V Svetitskaya, T A Snezhko, E A Kalabanova
Publikováno v:
Современная онкология, Vol 18, Iss 3, Pp 27-32 (2016)
The article shows the experience of eribulin application in actual clinical practice in Oncology institutions of the Russian Federation concerning metastatic breast cancer. We have analyzed the efficacy of the drug in case of different subtypes of th
Externí odkaz:
https://doaj.org/article/02544f99d49748aabf8218f99df2b907